COVID-19 Pandemic and IBS. Results of the All-Russian Observational Non-interventional Program to Study the Effectiveness of the Drug Kolofort® in Real Clinical Practice in Patients with Irritable Bowel Syndrome After a New Coronavirus Infection (VESNA)
Aim: to study the effectiveness and safety of using the drug Kolofort® in outpatients with irritable bowel syndrome (IBS) after a new coronavirus infection.Materials and methods. An observational non-interventional program was conducted in patients with exacerbation of IBS symptoms after a new coron...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2023-12-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/868 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860087306846208 |
|---|---|
| author | V. T. Ivashkin R. A. Abdulkhakov I. G. Bakulin S. V. Zaitsev V. I. Luchina S. N. Mekhtiyev S. G. Peshekhonov E. A. Poluektova T. I. Semenova S. N. Serikova G. N. Tarasova E. A. Trush Y. P. Uspenskiy I. B. Khlynov V. V. Tsukanov N. P. Chernus |
| author_facet | V. T. Ivashkin R. A. Abdulkhakov I. G. Bakulin S. V. Zaitsev V. I. Luchina S. N. Mekhtiyev S. G. Peshekhonov E. A. Poluektova T. I. Semenova S. N. Serikova G. N. Tarasova E. A. Trush Y. P. Uspenskiy I. B. Khlynov V. V. Tsukanov N. P. Chernus |
| author_sort | V. T. Ivashkin |
| collection | DOAJ |
| description | Aim: to study the effectiveness and safety of using the drug Kolofort® in outpatients with irritable bowel syndrome (IBS) after a new coronavirus infection.Materials and methods. An observational non-interventional program was conducted in patients with exacerbation of IBS symptoms after a new coronavirus infection. One hundred forty-one patients took part in the study. The final efficacy analysis included data from 127 study participants. All patients complained of increased/appearing gastrointestinal symptoms that appeared within 1–6 months after the infection (all patients had a history of COVID-19 infection). To assess the presence and severity of symptoms of the disease, the “7 × 7” questionnaire was used before the start of treatment and three months after the start of treatment.Results. At the stage of inclusion in the program, the average total score on the “7 × 7” questionnaire was 17.36, which corresponded to a moderately severe disorder. During the treatment period, the average total score decreased to 6.14, which corresponded to borderline disorder. In addition, significant improvement was observed for each symptom separately. After three months of therapy, doctors rated the overall impression of the treatment on a 5-point Likert scale from “very effective” to “ineffective”. The average score was 4.24. In addition, no serious adverse events were identified while taking the drug.Conclusion. In real clinical practice, the drug Kolofort® demonstrated high clinical efficacy in the treatment of patients with IBS after COVID-19 infection. |
| format | Article |
| id | doaj-art-de8bd1262f2a405590ca84aa3535b6ec |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2023-12-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-de8bd1262f2a405590ca84aa3535b6ec2025-02-10T16:14:38ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732023-12-01335415310.22416/1382-4376-2023-33-5-41-53571COVID-19 Pandemic and IBS. Results of the All-Russian Observational Non-interventional Program to Study the Effectiveness of the Drug Kolofort® in Real Clinical Practice in Patients with Irritable Bowel Syndrome After a New Coronavirus Infection (VESNA)V. T. Ivashkin0R. A. Abdulkhakov1I. G. Bakulin2S. V. Zaitsev3V. I. Luchina4S. N. Mekhtiyev5S. G. Peshekhonov6E. A. Poluektova7T. I. Semenova8S. N. Serikova9G. N. Tarasova10E. A. Trush11Y. P. Uspenskiy12I. B. Khlynov13V. V. Tsukanov14N. P. Chernus15I.M. Sechenov First Moscow State Medical University (Sechenov University)Kazan State Medical UniversityNorth-Western State Medical University named after I.I. MechnikovRegional Clinical HospitalCity Clinical Hospital No. 1Academician I.P. Pavlov First St. Petersburg State Medical UniversityDiagnostic and Treatment Centre “Zdorov'e”I.M. Sechenov First Moscow State Medical University (Sechenov University)City HospitalKuban State Medical UniversityRostov State Medical UniversityI.M. Sechenov First Moscow State Medical University (Sechenov University)Saint-Petersburg State Paediatric Medical UniversityUral State Medial UniversityFederal Research Center “Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences”, Research Institute of Medical Problems of the NorthI.M. Sechenov First Moscow State Medical University (Sechenov University); Consultative and Diagnostic Center No. 4 of the Moscow Health Department, Branch No. 3, Policlinic No. 2Aim: to study the effectiveness and safety of using the drug Kolofort® in outpatients with irritable bowel syndrome (IBS) after a new coronavirus infection.Materials and methods. An observational non-interventional program was conducted in patients with exacerbation of IBS symptoms after a new coronavirus infection. One hundred forty-one patients took part in the study. The final efficacy analysis included data from 127 study participants. All patients complained of increased/appearing gastrointestinal symptoms that appeared within 1–6 months after the infection (all patients had a history of COVID-19 infection). To assess the presence and severity of symptoms of the disease, the “7 × 7” questionnaire was used before the start of treatment and three months after the start of treatment.Results. At the stage of inclusion in the program, the average total score on the “7 × 7” questionnaire was 17.36, which corresponded to a moderately severe disorder. During the treatment period, the average total score decreased to 6.14, which corresponded to borderline disorder. In addition, significant improvement was observed for each symptom separately. After three months of therapy, doctors rated the overall impression of the treatment on a 5-point Likert scale from “very effective” to “ineffective”. The average score was 4.24. In addition, no serious adverse events were identified while taking the drug.Conclusion. In real clinical practice, the drug Kolofort® demonstrated high clinical efficacy in the treatment of patients with IBS after COVID-19 infection.https://www.gastro-j.ru/jour/article/view/868irritable bowel syndromepost-covid syndromefunctional diseases of the gastrointestinal tract |
| spellingShingle | V. T. Ivashkin R. A. Abdulkhakov I. G. Bakulin S. V. Zaitsev V. I. Luchina S. N. Mekhtiyev S. G. Peshekhonov E. A. Poluektova T. I. Semenova S. N. Serikova G. N. Tarasova E. A. Trush Y. P. Uspenskiy I. B. Khlynov V. V. Tsukanov N. P. Chernus COVID-19 Pandemic and IBS. Results of the All-Russian Observational Non-interventional Program to Study the Effectiveness of the Drug Kolofort® in Real Clinical Practice in Patients with Irritable Bowel Syndrome After a New Coronavirus Infection (VESNA) Российский журнал гастроэнтерологии, гепатологии, колопроктологии irritable bowel syndrome post-covid syndrome functional diseases of the gastrointestinal tract |
| title | COVID-19 Pandemic and IBS. Results of the All-Russian Observational Non-interventional Program to Study the Effectiveness of the Drug Kolofort® in Real Clinical Practice in Patients with Irritable Bowel Syndrome After a New Coronavirus Infection (VESNA) |
| title_full | COVID-19 Pandemic and IBS. Results of the All-Russian Observational Non-interventional Program to Study the Effectiveness of the Drug Kolofort® in Real Clinical Practice in Patients with Irritable Bowel Syndrome After a New Coronavirus Infection (VESNA) |
| title_fullStr | COVID-19 Pandemic and IBS. Results of the All-Russian Observational Non-interventional Program to Study the Effectiveness of the Drug Kolofort® in Real Clinical Practice in Patients with Irritable Bowel Syndrome After a New Coronavirus Infection (VESNA) |
| title_full_unstemmed | COVID-19 Pandemic and IBS. Results of the All-Russian Observational Non-interventional Program to Study the Effectiveness of the Drug Kolofort® in Real Clinical Practice in Patients with Irritable Bowel Syndrome After a New Coronavirus Infection (VESNA) |
| title_short | COVID-19 Pandemic and IBS. Results of the All-Russian Observational Non-interventional Program to Study the Effectiveness of the Drug Kolofort® in Real Clinical Practice in Patients with Irritable Bowel Syndrome After a New Coronavirus Infection (VESNA) |
| title_sort | covid 19 pandemic and ibs results of the all russian observational non interventional program to study the effectiveness of the drug kolofort r in real clinical practice in patients with irritable bowel syndrome after a new coronavirus infection vesna |
| topic | irritable bowel syndrome post-covid syndrome functional diseases of the gastrointestinal tract |
| url | https://www.gastro-j.ru/jour/article/view/868 |
| work_keys_str_mv | AT vtivashkin covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT raabdulkhakov covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT igbakulin covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT svzaitsev covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT viluchina covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT snmekhtiyev covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT sgpeshekhonov covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT eapoluektova covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT tisemenova covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT snserikova covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT gntarasova covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT eatrush covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT ypuspenskiy covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT ibkhlynov covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT vvtsukanov covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna AT npchernus covid19pandemicandibsresultsoftheallrussianobservationalnoninterventionalprogramtostudytheeffectivenessofthedrugkolofortinrealclinicalpracticeinpatientswithirritablebowelsyndromeafteranewcoronavirusinfectionvesna |